Affibody AB
556665-6913ActiveDeveloping next-generation radiopharmaceuticals using proprietary Affibody technology.
Yleiskatsaus
- 50–99
- Työntekijät
- 20–50milj SEK
- Liikevaihto
- 2004
- Perustettu
Avainpäättäjät
Peter Zerhouni
Chief Financial Officer and Chief Business Officer
David Bejker
President and Chief Executive Officer
Mathias Uhlén
Board Director
Anders Martin-Löf
Board Director
+11 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Affibody is a specialized biotechnology company focused on creating next-generation radiopharmaceuticals. They leverage their proprietary Affibody® platform to develop radioligand therapeutics (RLTs) designed for precision targeting. The company strategically focuses its pipeline on major cancer typ...
Tunnisteet
Avainsanat
Teknologiat
Yritystiedot
- Toimiala
- Bioteknisk forskning och utveckling
- Oikeudellinen muoto
- Aktiebolag
- ALV-numero
- SE556665691301
Päättäjät
15 yhteystietoa FunnelfeedrissäPeter Zerhouni
Chief Financial Officer and Chief Business Officer
David Bejker
President and Chief Executive Officer
Mathias Uhlén
Board Director
Anders Martin-Löf
Board Director
Jakob Lindberg
Board Director
Guido Wuerth
Head Corporate Development, Radiopharma
Karin Nord
Senior Vice President Research Operations
Fredrik Frejd
Chief Scientific Officer
Rachel Humphrey
Board Director
Robert Burns
Chair of the Board
Michael Monaghan
Board Director (Employee Representative)
Rezan Güler
Board Director (Employee Representative)
Filippa Stenberg
Board Director
Gillian M Cannon
Board Director
Jonathan Knowles
Board Director
Samankaltaiset yritykset
20 samankaltaista yritystä FunnelfeedrissäAffibody Medical AB
Developing next-generation radiopharmaceuticals using proprietary Affibody platform.
AAX Biotech AB
5–9 työntekijätResearch-driven biotech advancing antibody therapies via proprietary technology.
ZEALAND PHARMA A/S
0 työntekijätDeveloping peptide medicines for metabolic health challenges globally.
Oblique Therapeutics AB (publ)
10–19 työntekijätInnovative biotech developing breakthrough antibodies using the AbiProt platform.
Oncopeptides AB
20–49 työntekijätDeveloping targeted cancer therapies for difficult-to-treat diseases.
Selaa lisää
Kysymyksiä yrityksestä Affibody AB
Haluatko nähdä Funnelfeedrin toiminnassa?
Varaa ilmainen demo ja tutustu siihen, miten Funnelfeedr auttaa sinua löytämään ja konvertoimaan ihanteelliset asiakkaasi.
Varaa demo